Gynecologic Cancers | Clinical

Salani Reviews Role of PARP Inhibition in Ovarian Cancer

November 24, 2022

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.

The Role of Rucaparib in Ovarian Cancer Following the ARIEL4 Readout

October 22, 2022

In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.

The Role of Biomarker Testing in Ovarian Cancer

October 17, 2022

There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.